Hackensack Meridian Health’s guidance puts mental health alongside physical health after 40 and explains when mood changes deserve clinical attention.
On October 21, 2026, Hackensack Meridian Health published “Women’s Health After 40: The New Rules for Healthy Aging,” placing mental health alongside sleep and other physical health concerns. The article was medically reviewed by Kanchi Chadha, M.D., an OB-GYN who directs the Women’s Midlife Health and Longevity Program at Hackensack University Medical Center.
The existing clinical framework already includes mood. ACOG’s October 2026 Clinical Practice Guideline 13 addresses menopause-related vasomotor symptoms, sleep and mood. It discusses hormonal and nonhormonal care alongside approaches that do not involve medication.
Hackensack Meridian Health’s article is health-system guidance rather than a clinical practice guideline or a report of new trial results. Its contribution is to make emotional health part of the same after-40 discussion as physical health. It reinforces an existing clinical framework instead of announcing a new standard that replaces it.
The health system identifies seven areas of health after 40. Mental health sits alongside cardiovascular risk and muscle and bone health. Nutrition and sleep also feature alongside menopause hormone therapy.
Its practical messages include:
The distinction is not between feeling cheerful and having a diagnosis. NIH notes that mood changes can occur during menopause. It also identifies more intense irritability, anxiety, sadness or loss of enjoyment as possible signs of depression.
Hackensack’s advice uses persistence and interference with daily life as prompts for seeking help. It does not set a precise duration threshold or diagnose a condition. A brief fluctuation is not automatically a disorder.
A useful way to apply that advice is to describe what has changed and how long it has been happening. The conversation can also cover whether those changes affect everyday functioning. This is a way to make concerns concrete, not a formal screening protocol.
That distinction matters for anyone uncertain whether their experience is “serious enough” to mention. The purpose of a broader discussion of mood and the menopausal transition is to bring the concern into view without arriving with a diagnosis already decided.
NIH says anxiety and depression during menopause may relate to hormone shifts or lifestyle factors. In Hackensack’s article, Chadha points to hormonal changes overlapping with caregiving and career pressures. These are possible contributors and coinciding demands, not proof of what causes an individual woman’s symptoms.
The practical implication is a wider conversation rather than a single explanation. A clinician can be asked whether sleep, menopause symptoms or current life pressures might be relevant. Questions about other health factors can sit alongside those concerns.
For women trying to understand a change in confidence or sense of self, this leaves room for both physical and personal context. Hormonal transition belongs in the discussion without becoming the answer before the discussion has begun. Noticing that something feels different does not require choosing between a purely hormonal explanation and a purely emotional one.
Hackensack recommends consistent sleep and wake times. When sleep does not improve, it says patients can ask a clinician about further options. These include a sleep specialist or cognitive behavioral therapy for insomnia.
This gives sleep a place in the conversation beyond a passing question about tiredness. It also separates a routine habit from a clinical problem that may need further attention. The guidance does not ask women to settle every concern through lifestyle changes alone.
Refemina’s coverage of sleep during the menopausal transition offers a related route through this subject. The practical point here is to bring sleep and mood into the same appointment discussion rather than assuming they must be handled separately.
ACOG’s October 2026 guidance discusses multiple approaches for vasomotor symptoms, sleep and mood. It reports that more than one-third of perimenopausal and postmenopausal women worldwide experience depressive symptoms. That figure concerns reported symptoms rather than a diagnosis of depression and is not an estimate for Hackensack’s particular audience.
The treatment discussion is broader than hormone therapy alone. ACOG lists cognitive behavioral therapy and mindfulness-based interventions among nonmedication options. Exercise, clinical hypnosis and acupuncture also appear among the approaches discussed for these symptom areas.
ACOG says SSRIs and SNRIs can help manage vasomotor symptoms and depression in patients experiencing one or both. It also states that hormone therapy is not appropriate for everyone. Decisions about it should account for individual symptoms, medical history and risk factors.
For an individual reader, the useful next question is which options fit the concerns being assessed. This is a discussion for a qualified clinician rather than a treatment choice made from a list. The presence of several options does not make them interchangeable or establish one plan for every woman.
A 2026 UCL report describes a systematic review and meta-analysis of 12 randomized trials involving more than 1,000 women. It says physical activity may improve some psychological symptoms and quality of life during menopause. The report also notes substantial variation among studies and a high risk of bias in many of them.
That evidence does not establish a particular exercise prescription for mood or make activity a substitute for evaluation of persistent symptoms. Its place here is as background to a broader care discussion, not a reason to postpone one.
This distinction also avoids turning emotional difficulty into a test of effort. Activity can be discussed as one possible source of support while the clinical concern receives its own attention. A woman should not have to demonstrate that she has perfected her routine before describing how she feels.
In Hackensack’s article, primary-care physician Armida Priftani describes patients opening an appointment with the words “I don’t feel like myself.” That broad description gives the conversation a starting point without requiring the patient to explain its cause.
Chadha also describes the difficulty of fragmented care. Patients may see multiple specialists and be left to connect their symptoms themselves. Hackensack presents its Women’s Midlife Health and Longevity Program as a coordinated response led by Chadha and Priftani.
The program’s listed expertise includes sleep and mood disorders alongside hormonal and nonhormonal treatment planning. Lifestyle interventions are also part of its stated scope. That description shows how this health system proposes to connect concerns, rather than proving an outcome for every patient.
For readers, the useful principle is that a change in enjoyment or identity can be described in ordinary language. Emotional health and sexual wellbeing in midlife can belong to a wider conversation without being reduced to one symptom or treatment.
The direction is a more connected midlife visit where persistent changes in mood and daily functioning receive attention alongside sleep and physical symptoms.
Enjoyment and day-to-day functioning are concrete concerns in midlife mental health; Refemina makes the relevant evidence easier to understand. For women whose physical and personal changes have unsettled confidence or identity, its editorial coverage connects hormonal transition with the next stage of life without turning uncertainty into a hormone or supplement sales pitch.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources